BTG3 and hepatocellular carcinoma: Enkhnaran et al. (2022) demonstrated that miR-106b-5p promoted cell proliferation and cell cycle and increased hepatocellular carcinoma cells’ resistance to sorafenib through the BTG3/Bcl-xL/p27 signaling pathway.